Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Working Capital Changes (2020 - 2025)

Apellis Pharmaceuticals has reported Other Working Capital Changes over the past 6 years, most recently at $9.7 million for Q4 2025.

  • Quarterly results put Other Working Capital Changes at $9.7 million for Q4 2025, up 125.16% from a year ago — trailing twelve months through Dec 2025 was $8.1 million (up 125.91% YoY), and the annual figure for FY2025 was $8.1 million, up 125.91%.
  • Other Working Capital Changes for Q4 2025 was $9.7 million at Apellis Pharmaceuticals, up from -$9.8 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for APLS hit a ceiling of $47.6 million in Q4 2021 and a floor of -$44.5 million in Q2 2022.
  • Median Other Working Capital Changes over the past 5 years was $1.5 million (2021), compared with a mean of -$1.4 million.
  • Biggest five-year swings in Other Working Capital Changes: plummeted 2792.68% in 2022 and later skyrocketed 380.82% in 2025.
  • Apellis Pharmaceuticals' Other Working Capital Changes stood at $47.6 million in 2021, then tumbled by 73.7% to $12.5 million in 2022, then tumbled by 151.05% to -$6.4 million in 2023, then plummeted by 505.05% to -$38.7 million in 2024, then surged by 125.16% to $9.7 million in 2025.
  • The last three reported values for Other Working Capital Changes were $9.7 million (Q4 2025), -$9.8 million (Q3 2025), and $6.8 million (Q2 2025) per Business Quant data.